Overview

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate